Secukinumab

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 17.03.2024

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Secukinumab is a fully humanized monoclonal antibody against the cytokine IL-17A (see interleukins below), which is overexpressed in the pathogenesis of psoriatic inflammation (see psoriasis below) and plays a central role (see Th17 cell). The active ingredient is used in the treatment of various rheumatological diseases - also in psoriatic arthritis. The antibody secukinumab (AIN457) selectively binds to IL-17 and neutralises this cytokine.

Field of application/useThis section has been translated automatically.

Secukinumab was approved by the European Medicines Agency (EMA) in January 2015 for the primary systemic treatment of moderate to severe plaque psoriasis in adult patients requiring systemic treatment. This was followed in 2016 by an indication extension for psoriatic arthritis and ankylosing spondylitis (ankylosing spondylitis).

Also approved for children and adolescents 6-18 years since 07/31/2020!

Secukinumab has been shown to be successful in the treatment of psoriasis in several large studies. In the ERASURE1 study, 738 patients with moderate-to-severe psoriasis received either 300 or 150 mg of secukinumab or placebo subcutaneously at weeks 1, 2, 3, 4 and 8. At week 12, 81.6 percent (300 mg) and 71.6 percent (150 mg) of secukinumab patients, respectively, but only 4.5 percent of control patients met PASI-75 criteria. 65.3 vs. 51.2 vs. 2.4% of participants were largely free of clinical appearance, and > 40% of study participants achieved PASI-100 (complete clinical absence of appearance). The effect of secukinumab reached a maximum after 16 weeks and remained constant until week 52.

A follow-up study (A2304E1) to the pivotal SCULPTURE study, which covered a treatment period of 260 weeks, demonstrated that the initial response rate (69% PASI-90 response) was maintained over this 5-year observation period.

Several publications have described positive results in acrodermatitis continua suppurativa (Galluzzo M et al. (2019).

Complication(s)This section has been translated automatically.

Side effects observed with Secukinumab include nasopharyngitis, upper respiratory tract infections and headaches. Also herpes simplex labialis, oral candidiasis, urticarial exanthema, dyslipidemia (increase in cholesterol/triglycerides) and headaches. In rare cases (1-2% of patients) a (transient) neutropenia may occur (Altenburg A et al. 2018).

Dosage and method of useThis section has been translated automatically.

The recommended dose is 300 mg as a subcutaneous injection. The 300 mg dose can be administered as two injections of 150 mg each; meanwhile, the 300 mg unit is also available. After the first dose, additional weekly injections are initially given at weeks 1, 2, and 3, with injections at monthly intervals beginning at week 4. The total injected dose is always divided into 2 single doses of 150 mg.

In children: < 50 kg body weight 75 mg; >= 50 kg body weight 150 mg subcuan at week 0-1-2-3-4 and monthly thereafter.

PreparationsThis section has been translated automatically.

Cosentyx®

Note(s)This section has been translated automatically.

Secukinumab has been approved for the treatment of psoriasis under the trade name Cosentyx® by Novartis since mid-2015.

Good therapeutic successes have been described for psoriasis capitis (which is very difficult to treat topically) (Bagel J et al. 2017)

Recently, successful treatment with secukinumab was described for the rare SAM syndrome(severe dermatitis, multiple allergies and metabolic wasting) (Cao Q et al. 2023).

LiteratureThis section has been translated automatically.

  1. Adami S (2014) The Role of Interleukin-17A in Psoriatic Disease. BioDrugs 28:487-497
  2. Altenburg A et al. (2018) Biological side effects in psoriasis. Dermatologist 69: 290-297
  3. Bagel J et al. (2017) The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a
  4. 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol 77:667-674.
  5. Blauvelt A et al. (2014) the FEATURE Study Group. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol 172: 484-492.
  6. Böhner A et al. (2016) Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab. JAMA Dermatol 152:482-484.
  7. Cao Q et al. (2023) Successful Treatment of SAM Syndrome With Secukinumab Monotherapy: A Case Report of a 16-Month-Old Infant. Dermatitis. doi: 10.1089/derm.2023.0222.
  8. Chiricozzi A (2014) Pathogenic role of IL-17 in psoriasis and psoriatic arthritis. Actas Dermosifiliogr 105 Suppl 1:9-20
  9. Galluzzo M et al. (2019) Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature. Dermatol Ther 32:e12899.
  10. Lønnberg AS et al. (2014) Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Invest Dermatol 15:251-259
  11. Ohtsuki M et al. (2014) ERASURE Study Japanese subgroup. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol 41:1039-1046
  12. Paul C et al. (2014) the JUNCTURE study group. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol doi:10.1111/jdv.12751.
  13. Sobell JM et al. (2014) Therapeutic development in psoriasis. Semin Cutan Med Surg 33 (4 Suppl): 69-72

Authors

Last updated on: 17.03.2024